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Background: Acute coronary syndromes (ACS) are complex and polygenic diseases which are a real problem of
public health. These syndromes require multidisciplinary studies to understand the pathogenesis mechanisms and
metabolic interactions between different risk factors.This study aimed to explore the variation of two coronary risk
parameters not mentioned by Framingham cohorts, hyperhomocysteinemia and endothelin-1 (ET-1) in Tunisian
coronary and the study of the variation of these parameters based on various cardiac risk factors and metabolic
relationship between them.To 157 coronary and 142 healthy subjects, the concentration of homocysteine was
quantified by fluorescence polarization immunoassay; the concentration of ET-1 was measured by an analytical
technique, the High Performance Liquid Chromatography (HPLC) coupled with mass spectrometry.
Results: Our study showed that homocysteine and ET-1 were significantly higher in patients compared to healthy
subjects (24.40 ± 12.5 μmol/L vs 7.44 ± 2.5 μmol/L p <0.00001) for homocysteine and (15.2 ± 5.3 nmol/L vs 7.1 ±
2.7 nmol/L, p <0.00001) for ET-1. On the other hand, homocysteine varies according to tobacco and diabetes while
ET-1 depends on the sex, hypertension, smoking, obesity and dyslipidemia and a statistically negative correlation
was shown between homocysteine and ET-1 in coronary patients (r = −0.66 p <0.00001).
Conclusion: The study of the variation of these two parameters in coronary patients and metabolic exploration of
the relationship between homocysteine and ET-1 according to various risk factors and the interactions between
themselves facilitates the decision of therapeutic treatment.
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Acute coronary syndrome (ACS) is a major cause of
morbidity and mortality worldwide. Recently, an increase
in the incidence of ACS has been recorded in Tunisian
cardiovascular disease register. Among diabetes, hyper-
tension, obesity and smoking, a family lipoprotein
disorder such as a high level of serum apolipoprotein B
(Apo B) or/and a lower level of serum apolipoprotein
A-1 accounted for almost all the population attributable
risk of ACS, according to the Framingham study [1, 2].* Correspondence: abdelkader.chalghoum@yahoo.fr
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creativecommons.org/publicdomain/zero/1.0/To today, hyperhomocysteinemia and endothelin-1
(ET-1) are considered two “unconventional” coronary
risk markers not classified by the Framingham cohorts,
The increase in serum homocysteine (demethylated
methionine) 10 μmol/L are associated with amplification
of coronary risk for 80 %, independently of the origin of
this increase (genetic, nutritional, drug …). This risk is
related to the harmful effects of homocysteine specially
on endothelium tissue [2, 3].
The same for ET-1, potent vasoconstrictor secreted by
endothelial cells (21 amino acids) and heavily involved in
the genesis and complications of ACS by their pro-oxidant
effect, pro-aggregating effect and pro-thrombotic effect
associated with the major vasoconstrictor effect [4, 5].ess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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quantify the serum concentration of homocysteine and
to measure the ET-1 serum concentration in Tunisians
coronary compared to healthy subjects, investigate the
impact of various risk factors on serum variation of
these two parameters as well as the study of the correl-
ation between these two markers.
Result
Clinical characteristics and biochemical parameters of
patients with coronary artery syndrome and healthy group
are illustrated in Table 1. No significant difference







Age (x ± σ years) 64.8 ± 11.7 56.8 ± 9.4 NS
Sex
Men (%) 121 (77 %) 111 (78.2 %) NS
Women (%) 36 (23 %) 31 (21.8 %) NS
BMI (kg /m2) 27.6 ± 4 23.3 ± 2.2 NS
Hypertension (%) 88 0 -
Obesity (%) 52 8.5 % -
Diabetes (%) 64 0 -
Smoking (%) 62.4 7 -
Family cardiac history (%) 68 6 -
Personnel cardiac history (%) 66 0 -
Post menopausal women (%) 100 82 -
Dyslipidemia (%) 40 0 -
Sedentary (%) 43 11 -
Alcohol (%) 33 14 -
Glucose (x ± σ mmolL/) 9.8 ± 4.2 5.40 ± 0.84 <0.0001
TC (x ± σ mmol/L) 5.70 ± 3.1 4.60 ± 2.6 <0.001
HDL-C (x ± σ mmol/L) 1.14 ± 0.22 1.30 ± 0.41 NS
LDL-C (x ± σ mmol/L) 3.60 ± 2.16 2.80 ± 1.4 <0.001
TG (x ± σ mmol/L) 1.60 ± 0.9 1.24 ± 0.3 NS
ApoA1 (x ± σ. g/L) 1.41 ± 0.62 1.80 ± 0.2 <0.00001
ApoB (x ± σ. g/L) 1.40 ± 0.81 0.70 ± 0.2 <0.00001
Treatment
ACA-1 inhibitors (%) 97 0 -
Statins (%) 38 0 -
Beta-Blokers (%) 33 0 -
Ca-Blokers (%) 27 0 -
Diuretics (%) 17 0 -
ApoA apolipoprotein A, ApoB apolipoprotein B, BMI body mass index, HDL-C
high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol,
TC total cholesterol, TG triglycerides, x mean, σ standard deviation, NS
not significantage and sex. For cardiovascular risk factors, diabetes,
hypertension, smoking and dyslipidemia are greatly
mentioned among patients compared with healthy
subjects. Apolipoproteins disorder was observed in
patients. There was a significant increase in serum
Apo B level (p <0.00001) and a decreased serum Apo
A-1 level (p <0.00001) compared with serum apolipo-
protein levels in healthy subjects.
Furthermore, homocysteinemia and ET-1 concentra-
tion were significantly elevated in patients compared to
controls (p <0.00001, for both comparisons). Table 2
showed this variation and as well as the study of homo-
cysteinemia and ET-1 concentration in patients according
gender and cardiovascular risk factors. This investigation
shows that ET-1 depends on gender, arterial hypertension,
tobacco, obesity and dyslipidemia, unlike diabetes, alcohol
and physical inactivity, which are not involved in this vari-
ation. For homocysteine, it only depends on tobacco and
diabetes.
Besides to that, a negative statistically correlation was
found (r = −0.66 p <0.00001) between homocysteinemia
and ET-1 concentration (Fig. 1).
Discussion
Varied risk factors among patients group confirm the
multifactorial and polygenic origin of the ACS, well ex-
plained by the Framingham study. The lipid profile of
patients was partially balanced because the hypolipid-
emic treatment, essentially the angiotensin-1 converting
enzyme inhibitors with its beneficial effects against
metabolic syndrome and lipid complications [2].
The increased of apolipoprotein B concentrations in
patients consolidate its atherogenic effects and its in-
volvement in the ACS genesis, although the majority of
patients are under statins and anti-hypertensive medica-
tion. Unlike reversible dyslipidemia (only related to diet
and lifestyle), easy to corrected by statins, mixed and
genetic dyslipidemia requires a combined medication
(statins + fibrates, or nicotinic acid) [6, 7].
Whereas, Apo A1 (statistically higher in healthy group)
has a cardio-protective effect [2, 8, 9].
Statistically significant elevation of homocysteine sug-
gests an impact of this parameter in the ACS genesis and
complications. In indeed, the implication of hyperhomo-
cysteinemia in cell injury of the vessel wall, vascular con-
nective tissue, oxidative imbalance and prothrombotic
effect is well described in various prospective studies.
Hyperhomocysteinemia is strongly incriminated in the
liberation of von Willebrand factor, in activation of V and
VIII factors of coagulation, in inhibition of C and S pro-
teins, in lipid peroxidation… These effects combine, and
accelerate of the atherosclerotic plaque formation and
contributing to subsequent thrombotic and ischemic com-
plications [2, 9].
Table 2 The distribution of Homocysteinemia and, ET-1 concentration patients and healthy subjects and according to risk factors
among patients
Populations and risk factors Hcy (μmol/L) P ET-1 (nmol/L) P
Population Patients (n = 157) 24.40 ± 12.5 <0.00001 15.2 ± 5.3 <0.00001
Controls (n = 142) 7.4 ± 2.5 7.1 ± 2.7
Gender Men (n = 121) 24.8 ± 18.2 NS 17.4 ± 4.6 <0.00001
Women (n = 36) 23.1 ± 6.3 7.8 ± 2.3
Hypertension Yes (n = 138) 24 ± 8.3 NS 16.4 ± 3.3 <0.00001
No (n = 19) 27.3 ± 16.7 6.6 ± 1.9
Diabetes Yes (n = 101) 29.4 ± 7.6 <0.00001 15 ± 5.1 NS
No (n = 56) 15.4 ± 6.6 15.6 ± 3.8
Tobacco Yes (n = 98) 32.4 ± 11.6 <0.00001 11.6 ± 3 <0.00001
No (n = 59) 11.1 ± 2 21.2 ± 6.1
Obesity Yes (n = 82) 28.2 ± 13 NS 12.2 ± 5.3 <0.001
No (n = 75) 20.2 ± 5.3 18.2 ± 4
Dyslipidemia Yes (n = 63) 26.2 ± 8.2 NS 11.8 ± 1.6 <0.00001
No (n = 94) 23.2 ± 7.4 17 .5 ± 4.6
Alcohol Yes (n = 52) 24.9 ± 10.6 NS 16 ± 4.1 NS
No (n = 105) 24.2 ± 7.3 14.8 ± 3.8
Sedentarity Yes (n = 67) 25.7 ± 11.1 NS 15.7 ± 3.7 NS
No (n = 90) 23.5 ± 7.5 14.9 ± 2.4
σ standard deviation, NS not significant, x mean, Hcy homocysteine, ET-1 endothelin-1
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cording to its severity into three types (moderate, inter-
mediate and severe), the first with a lower concentration
(<30 μmol/L), the second with a range between 30 and
100 μmol/L, and the third defined by a higher concen-
tration (>100 μmol/L). The first type is the most domin-
ant in the world because it is metabolic and dietary
origin usually reversible and easy to corrected, while
intermediates and severe hyperhomocysteinemia are the
most serious and difficult to correct because they are
often genetically determined (caused by homozygous
mutations in the genes responsible for the degradation
of homocysteine). Statistically, they are the least fre-
quent, which is well defined in our study, with domin-
ance of moderate hyperhomocysteinemia, a minority are
intermediate or severe and they are also behind of the
big variability to this marker in patients [10, 11].
Statistically significant elevation of homocysteine in
smoking and obese coronary is associated with the
implication of obesity and smoking in the metabolic
syndrome genesis and complications, the latter is proved
responsible for lipid disorder and hepatic depletion, in
an advanced stage, the liver will be unable to metabolize
excess homocysteine (by secretion of degradation and/or
correction enzymes) [2, 12–14].
In addition, Our study showed a statistically significant
increase in the ET-1 values among patients compared tocontrol subjects, which reflects its role not only in pro-
longed vasoconstriction but also its atherogenic impact, its
pro-oxidant effect and its pro-aggregating role [4, 15].
The high concentration of ET-1 among men patients
compared to women patients shows the effect of the
male gender as an un-modifiable cardiovascular risk
factor.
This increase of ET-1 level is of metabolic origin and
non-genetic, since our peptide is expressed by an auto-
somal gene (located on chromosome 6) and the same
thing for cleavage and maturation enzymes (endo-
thelin-1 converting enzyme…) are also derived from
autosomal genes [16].
The elevated concentration of ET-1 among hyperten-
sive patients compared with normotensive patients is
explained by the vasoconstrictor effect of ET-1 and its
roles in the sodium reabsorption. In hyperactivity, these
regulatory effects become hypertensive [4].
The ET-1 concentration was inhibited by smoking,
obesity and dyslipidemia, this inhibition is explained in
the literature by the roles of these factors in the genesis
and complications of metabolic syndrome [17]. The
latter is responsible for the liver impotence in degradation
and neutralization of cytotoxic elements (that infect the
endothelium, main secretory tissue of ET-1). In addition,
nicotine has a harmful effect on the endothelium and pre-
vents secretion of endothelial factors [17–19].
ET-1 (nmol/L)               
Homocysteine (µmol/L)         
Fig. 1 The negative correlation between homocysteine and ET-1 concentration in patients population (r = −0.66, p < 0.00001)
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diabetes was not implicated in the change of ET-1 con-
centration because the drug used and the recommended
diet [20, 21].
Statistically negative correlation between homocysteine
and ET-1 (Fig. 1) is explained by the impact of metabolic
syndrome in the liver impotence in the neutralizing of
homocysteine. This demethylated methionine causes
serious and irreversible damage (necrosis, apoptosis…) in
the endothelium; principal secretory tissue of ET-1. With
a similar mechanism, tobacco (a major actor of the meta-
bolic syndrome) inhibits the metabolism of the homocyst-
eine and blocks the secretion of the ET-1 due to the
adverse effects of nicotine on the endothelial tissue [2, 22].
Our result is supported by the study of Drunat S et al.
[23], who experimentally showed that homocysteine is
responsible for the braking of the transcription of the gene
which expresses the pre-pro-endothelin-1 (inactive pre-
cursor of ET-1). According to his study, an endothelial cell
line treated by homocysteine has a low level of mRNA of
the pre-pro-endothelin-1 compared to an untreated line.
Conclusion
Although they are negatively correlated, hyperhomocys-
teinemia and increase of ET-1 concentration appearsinvolved not only in the susceptibility to ACS, but also
in the subsequent complications and in other patholo-
gies, including kidney diseases [24]. These two parame-
ters vary differently depending on the risk factors that
reflect the complexity of ACS, even the risk markers can
be negatively correlation a specific stage of the disease.
Methods
Populations study
This is a prospective study, in which, sampling was carried
between January 2010 and November 2011. 157 Tunisian
coronary subjects (121 men and 36 women) middle-aged
(64.8 ± 11.7 years) were recruited from the Cardiology
Service of Farhat Hached Hospital of Sousse, Tunisia. 142
healthy subjects (111 men and 31 women) middle-aged
(56.8 ± 9.4 years) were considered as the healthy group.
The patients and healthy subjects signed a free and clear
consent which explains the objectives of this work with an
undertaking not to publish the names of participants, their
personal data including test results (following the instruc-
tions of National Committee of Medical Ethics, in Tunisia,
consistent with the Declaration of Helsinki).
A datasheet had been prepared for each subject
(patient or healthy individual) to identify cardiovascular
risk factors and to know the susceptibility degrees to
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teristics, the biological parameters, the risk factors, the
treatments of patients.Laboratory analysis
Venous blood samples were drawn after 12 h overnight
fast. A collection of two tubes were made for each
patient and witness: one tube without anticoagulant for
Homocysteinemia, ET-1 concentration, lipid profile and
apolipoprotein and the second tube with Heparin Lithium
for glycemia.
A simple biochemical investigation (blood glucose, lipid
profile) was done by colorimetric essay (Randox-Antrim,
UK), LDL-C was determined by Friedewald formula for
TG levels which does not exceed 4.5 mmol/L and apolipo-
proteins (Apo A1, Apo B) measurements by a immunone-
phelemetry essay (Cobas Integra 400, Roche) to explore
the risk of exposure to acute Coronary syndrome in pa-
tients and healthy group.
The homocysteine was quantified by an immunoassay
fluorescence polarization immunoassay (FPIA) (Abbott
AxSYM-Diagnostics, Wiesbaden, Germany).
After plasmatic ET-1 extraction with ethanol, its con-
centration was measured by High Performance Chroma-
tography, coupled to Mass Spectrometry (3200 Q TRAP
LC/MS/MS system), according to the Walczak M proto-
col, 2010 [5], using a synthetic standard (ET-1 Sigma-
Aldrich St. Louis, MO, USA) for the specific spectra
identification and for the calibration curve determining.
Chromatographic separation was carried out with C18
analytical column (30 mm × 2.1 mm, 3.5 μm, Waters
Ireland) set at 20 °C. Two solvents mixtures were used:
solvent A: Acetonitrile and solvent B: H2O. The follow-
ing gradient was used: 0–5 min 0–100 % A; 5–7 min
100 % A; 7–8, 100-0 % A; 8–15 min, 100 % B. The flow
rate was set at 300 μLmin−1 and a sample volume of
25 μL was injected in the analytical column.
Our biochemical analyzes were carried immediately
after blood sampling, excepting the quantification of ET-1,
which started in October 2012 and the samples were
stored in −80 °C according to our reference protocol [5].Statistical analysis
Database management and statistical analyses were
carried out using SPSS, version 21.0. Results are presented
as means ± SD, or percentages. Means were compared
using Student test. The relations between variables were
assessed with Pearson’s correlation analysis. The signifi-
cance threshold was set at 5 % (p < 0.05).
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